Parallel group controlled, dose-escalation study to assess the safety, tolerability, efficacy of YS-1402 combined with CABG for patient with ischaemic cardiomypathy

Parallel group controlled, dose-escalation study to assess the safety, tolerability, efficacy of YS-1402 combined with CABG for patient with ischaemic cardiomypathy - Parallel group controlled, dose-escalation study to assess the safety, tolerability, efficacy of YS-1402 for ischaemic heart disease in CABG

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015514

Enrollment

Registered

2015-06-01

Start date

2015-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICM

Interventions

Transplantation of gelatinous preparation contains 10mg of YS-1402 to the heart Transplantation of gelatinous preparation contains 30mg of YS-1402 to the heart Transplantation of gelatinous preparatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ischaemic heart disease who underwent CABG echocardiography EF<=40%

Exclusion criteria

Exclusion criteria: Cancer pregnancy Alcoholics and drug dependense in medical history

Design outcomes

Primary

Measure	Time frame
Safety for YS-1402	—

Countries

Japan

Contacts

Public ContactMatsuura,ryohei

Osaka University Hospital cardiovascular surgery

t-saito@surg1.med.osaka-u.ac.jp06-6879-3154

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026